Table 3

PRS by factors other than initial treatment regimen (n = 272)

Characteristic3-year postrelapse survival ± SE % (n)Log-rank P
Timing from diagnosis, mo   
    < 36 30.0 ± 3.7 (190) < .0001 
    ≥ 36 57.8 ± 6.4 (82)  
Site   
    All 38.1 ± 3.3 (272)  
    Marrow (±EMD) 29.7 ± 3.7 (186) < .0001 
    Isolated CNS 52.2 ± 7.4 (66)  
    Other isolated EMD 68.2 ± 11.6 (20)  
Sex   
    Male 38.2 ± 4.2 (173) .92 
    Female 37.9 ± 5.4 (99)  
Age at initial diagnosis, y   
    1-9 48.6 ± 5.3 (106) .001 
    10-15 35.4 ± 5.0 (132)  
    16-20 14.7 ± 6.8 (34)  
Lineage   
    B 40.5 ± 3.9 (193) .09 
    T 29.2 ± 8.2 (46)  
Characteristic3-year postrelapse survival ± SE % (n)Log-rank P
Timing from diagnosis, mo   
    < 36 30.0 ± 3.7 (190) < .0001 
    ≥ 36 57.8 ± 6.4 (82)  
Site   
    All 38.1 ± 3.3 (272)  
    Marrow (±EMD) 29.7 ± 3.7 (186) < .0001 
    Isolated CNS 52.2 ± 7.4 (66)  
    Other isolated EMD 68.2 ± 11.6 (20)  
Sex   
    Male 38.2 ± 4.2 (173) .92 
    Female 37.9 ± 5.4 (99)  
Age at initial diagnosis, y   
    1-9 48.6 ± 5.3 (106) .001 
    10-15 35.4 ± 5.0 (132)  
    16-20 14.7 ± 6.8 (34)  
Lineage   
    B 40.5 ± 3.9 (193) .09 
    T 29.2 ± 8.2 (46)  

EMD indicates extramedullary disease; and CNS, central nervous system.

Close Modal

or Create an Account

Close Modal
Close Modal